IRIS
MUSUMECI, FRANCESCA MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.183
Totale 6.183
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 6.183
Totale 6.183
Salva come PNG Salva come JPEG
Città #
Genova 4.326
Genoa 821
Rapallo 812
Vado Ligure 210
Bordighera 14
Totale 6.183
Salva come PNG Salva come JPEG
Nome #
Fyn kinase in brain diseases and cancer: the search for inhibitors. 146
Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma. 138
Analogs, formulations and derivatives of imatinib: A patent review 134
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma 128
A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors. 127
ATP-competitive inhibitors of mTOR: an update. 126
Click Chemistry, A Potent Tool in Medicinal Sciences 126
Src kinase inhibitors: an update on patented compounds 117
Bcr-Abl tyrosine kinase inhibitors: A patent review 117
In silico identification and biological evaluation of novel selective serum/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold 116
The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme 116
Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. 115
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant 113
An update on dual Src/Abl inhibitors 108
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment 106
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors 104
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia 103
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells 103
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. 102
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. 101
CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction. 100
Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells 100
Novel dual Src/Abl inhibitors for hematologic and solid malignancies. 96
Water Solubility Enhancement of Pyrazolo[3,4-d]pyrimidine Derivatives via Miniaturized Polymer–Drug Microarrays 96
SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation 95
Pyrrolo[2,3-d]pyrimidines as kinase inhibitors 95
A1 receptors ligands: past, present and future trends. 92
Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies 91
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction 91
Selective chemical oxidation of risperidone: a straightforward and cost-effective synthesis of paliperidone 88
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. 88
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model 87
Matrine in association with FD‑2 stimulates F508del‑cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809 85
Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors 84
The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells 82
An Update on JAK Inhibitors 79
Hck inhibitors as potential therapeutic agents in cancer and HIV infection 78
Substituted pyrazolo[3,4-b]pyridines as human A(1) adenosine antagonists: Developments in understanding the receptor stereoselectivity 77
3-Cyano-4,6-diphenyl-pyridine amino acid derivatives active as influenza A polymerase inhibitors 75
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives active against the T315I Abl mutation. 75
Starch/Poly(glycerol-adipate) Nanocomposites: A Novel Oral Drug Delivery Device 74
Synthesis of pyrazolo[3,4-d]pyrimidines active on Bcr-Abl T315I mutation. 72
Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors 69
One-pot synthesis of indolyl- pyrrolones as Pim1 inhibitors 68
Synthesis of new pyrazolo[3,4-d]pyrimidines 6-alkyl substituted Bcr-Abl tyrosine kinase inhibitors 68
Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors 68
In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity 68
Formulation Of Pyrazolo[3,4-d]pyrimidines Kinase Inhibitors For The Treatment Of Glioblastoma Multiforme 67
Exploring SAR of a new generation of pyrazolo[3,4-d]pyrimidines as Fyn tyrosine kinase inhibitors 66
Synthesis of a small library of potential SGK1 inihibitors 66
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines 66
Pyrazolo[3,4-d]pyrimidine active on neuroblastoma cells 65
6-Substituted pyrazolo[3,4-d]pyrimidines: new promising compounds in the fight against Neuroblastoma 64
SGK1 as a new target for anticancer agents: a hit-to-lead study 64
Synthesis of heterocyclic compounds to be tested as potentiators or correctors of mutant CFTR in cystic fibrosis 63
The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cells 63
Pyrazolo[3,4-d]pyrimidines as tyrosine kinase inhibitors: synthesis and biological evaluation 62
Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists. 61
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives active in a preclinical glioblastoma model. 60
Synthesis of a new generation of pyrazolo[3,4-d]pyrimidine as SGK-1 inhibitors. 59
Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4-d]pyrimidines Kinase Inhibitors 58
Synthesis of a new generation of pyrazolo[3,4-d]pyrimidines as Fyn inhibitors 57
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives endowed with activity against the T315I Abl mutation 50
The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the64CuCl2in Human Glioblastoma Multiforme Cells 49
Formulated pyrazolo[3,4-d]pyrimidines active on GBM cell lines 49
Insight into Fyn and SGK1 kinases as new targets in medicinal chemistry: design and synthesis of pyrazolo[3,4-d]pyrimidine libraries 48
Identification of a new family of pyrimidine and pyridine derivatives as disruptors of the viral RNA-dependent RNA polymerase 44
Synthesis of a new series of optimized pyrazolo[3,4‑d]pyrimidines as Src Inhibitors 41
null 40
Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells 34
Design, synthesis, and biological evaluation of a new series of pyrazolo[3,4-d]pyrimidines active as SGK1 inhibitors. A lead optimization study. 34
Development of a new potential theranostic prodrug for targeting glioblastoma multiforme 33
Insights into RNA-dependent RNA Polymerase Inhibitors as Anti-influenza Virus Agents 33
PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AS SIRTUIN INHIBITORS: DESIGN, SYNTHESIS AND PRELIMINARY in vitro EVALUATION 32
Synthesis of hybrid small molecules as potential PA-PB1 heterodimer disruptors of Influenza virus Polymerase 31
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma 31
Combining repositioning and de novo synthesis of pyrazolo[3,4-d]pyrimidines to discover potent SIRT-2 inhibitors 28
Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment 26
Synthesis of a new generation of potential anti-influenza agents targeting the PA-PB1 protein-protein interaction. 26
Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors 25
New potential anti-flu agents acting by disrupting the PA-PB1 interaction of viral polymerase. 24
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment 23
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling 22
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment 21
Design and synthesis of a new series of pyrazolo[3,4- d]pyrimidines active as SGK1 inhibitors in ovarian cancer cell models 20
SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW 4-AMINO-PYRAZOLO[3,4-d]PYRIMIDINES AS POTENTIAL SRC KINASE INHIBITORS 20
In silico exploration of LANCL2-ABA binding mode towards the identification of novel LANCL2 agonists 19
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme 15
New Insights into the LANCL2-ABA Binding Mode towards the Evaluation of New LANCL Agonists 11
IN SILICO INVESTIGATION OF LANCL-2 ACTIVATION MECHANISM: THE CASE OF BT-11 (OMILANCOR). 11
Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor 10
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective 6
Structure-Based Virtual Screening (SBVS) for the discovery of Sirtuin-2 inhibitors 6
Inhibition of serum- and glucocorticoid-induced kinase 1 ameliorates hydrocephalus in preclinical models 5
A family of nitrogen-containing heterocycles as sirtuin inhibitors: synthesis and invitro biological evaluation 5
Sweet Cherry Extract as Permeation Enhancer of Tyrosine Kinase Inhibitors: A Promising Prospective for Future Oral Anticancer Therapies 4
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA–PB1 Subunits Interaction 4
Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme 3
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted Therapy 2
Totale 6.413
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.300
article - articoli 15.544
book - libri 0
conference - conferenze 5.756
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.600
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.658 0 0 58 97 149 169 280 148 169 300 233 55
2020/2021673 37 39 32 24 51 71 115 56 59 81 49 59
2021/2022891 16 38 77 104 18 76 37 214 75 62 40 134
2022/2023997 95 90 7 133 125 164 0 72 173 8 115 15
2023/2024658 19 76 17 94 45 52 34 25 38 43 66 149
2024/2025246 48 124 74 0 0 0 0 0 0 0 0 0
Totale 6.413